Citigroup’s Apellis Pharmaceuticals APLS Stock Holding History

Citigroup’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-29,000	Closed	-$925K	–	5554
2024 Q4	$925K	Buy	+29,000	New	+$872K	﹤0.01%	3419
2024 Q2	–	Sell	-89,700	Closed	-$5.27M	–	5569
2024 Q1	$5.27M	Buy	+89,700	New	+$5.72M	﹤0.01%	1674
2023 Q4	–	Sell	-30,000	Closed	-$1.14M	–	5682
2023 Q3	$1.14M	Buy	30,000 +10,000	+50%	+$439K	﹤0.01%	2397
2023 Q2	$1.82M	Sell	20,000 -4,900	-20%	-$423K	﹤0.01%	2307
2023 Q1	$1.64M	Buy	24,900 +200	+0.8%	+$11.5K	﹤0.01%	2157
2022 Q4	$1.28M	Sell	24,700 -10,300	-29%	-$546K	﹤0.01%	2398
2022 Q3	$2.39M	Buy	35,000 +29,400	+525%	+$1.74M	﹤0.01%	2022
2022 Q2	$253K	Sell	5,600 -6,600	-54%	-$301K	﹤0.01%	3706
2022 Q1	$620K	Buy	+12,200	New	+$539K	﹤0.01%	3357

Other funds holding APLS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citigroup's APLS Position: Q1 2026 in Review

Citigroup increased its Apellis Pharmaceuticals (APLS) stake by 5.6% in Q1 2026, buying an estimated $756K and bringing the position to 657,223 shares worth $26.4M. The position accounts for 0.01% of the portfolio, ranked #929.

Citigroup first reported a position in APLS in Q4 2017 and has held it in 34 quarters since. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

Citigroup held 657,223 shares of Apellis Pharmaceuticals worth $26.4M as of Q1 2026.
Citigroup bought 35,065 Apellis Pharmaceuticals shares in Q1 2026, an estimated $756K.
Apellis Pharmaceuticals made up 0.01% of Citigroup's portfolio in Q1 2026, its #929 holding.
Citigroup first reported a position in Apellis Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.